jpg A re-analysis of the RADIANT-2 trial, which evaluated everolimus (Afinitor) in patients with advanced nonpancreatic neuroendocrine tumors, has yielded prognostic factors that identify a group of patients who are not only at high risk for recurrence but whoCaroline Helw...
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. J Clin Oncol 2011; ... P Ruszniewski,P Tomassetti,S Saletan,... - 《Journal...
摘要: Octreotide LAR has been the foundation of NET therapy; however, additional treatment options are needed. Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase II studies....
Check for the trial license extension New version was installed. It has to be activated before you can begin to use it. Hardware change was detected. You need to reactivate the software. Your license includes free updates until %s.This version was built on %s.You need to buy subscription...
You may request a free trial for Radiant Media Player at:https://www.radiantmediaplayer.com/free-trial.html. Back to documentation sections Releases123 16.1.1Latest Dec 17, 2024 + 122 releases Packages No packages published Languages JavaScript88.5% ...
Font Download: To download this font, you needSVIP Membershipand100zicoins, pleasesign into download the font! The RadiantDisplayEFCE-No4 ☞ download service (free or paid) provided by FontKe is only for personal trial and shall not be used for any commercial purpose. ...
Font Download: To download this font, you needSVIP Membershipand100zicoins, pleasesign into download the font! The RadiantEFText-Light ☞ download service (free or paid) provided by FontKe is only for personal trial and shall not be used for any commercial purpose. ...
Post-progression therapies in patients with advanced neuroendocrine tumors (NET): Analysis from the RADIANT-2 trialHobday, TBecerra, CYalcin, SPanneerselvam, ASaletan, SHainsworth, J
The phase III placebo-controlled RADIANT-2 trial investigated the efficacy of everolimus plus octreotide long-acting repeatable (LAR) in patients with adva... Lowell,B,Anthony,... - 《Neuroendocrinology》 被引量: 23发表: 2015年 加载更多来源...
6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)doi:10.1016/S0959-8049(11)71877-9Ricci, S....